
EudraGMDP is the European database of manufacturing and import authorisations, GMP certificates and statements of non-compliance with GMP. It is maintained by EMA, and a[…]

The FDA holds a hybrid public meeting on 16 September 2026 on reauthorisation of the Prescription Drug User Fee Act, with comments open until 16[…]

On 1 September 2026 EMA launched a voluntary data submission pilot for New Approach Methodologies — the organ-on-chip systems, human tissue models, organoids and computational[…]

EMA adopted a revised Guideline on the chemistry of active substances (EMA/CHMP/QWP/49484/2026), published on 20 March 2026 and now the current effective version. It is[…]

On 4 September 2026 EMA announced that its safety committee, PRAC, has started a review of injectable iron-containing medicines over the risk of hypophosphataemia —[…]

A referral takes a medicine out of the hands of its marketing authorisation holder and puts it in front of the entire European regulatory network.[…]

An audit finding is cheap. What it costs is determined entirely by what happens next. Inspectors across GMP, GDP, pharmacovigilance and medical device frameworks pay[…]

Manufacturing is audited. Laboratories are audited. Pharmacovigilance is audited because the law requires it. Regulatory affairs — the function that owns the dossier, the commitments,[…]

Chapter 9 of the EU GMP Guide is one of the shortest chapters in the guide and one of the most revealing. Self-inspection is the[…]

Cosmetics are not authorised before they reach the EU market, and that absence of a pre-approval step misleads people about how regulated the sector actually[…]